Immunologic Factor – Page 26

Moderna CEO Reflects on 2024 Challenges and Advances in Shareholder Letter

8 months ago talkbio0Tagged 2024, COVID19 (disease), Letter [Publication Type], Moderna, mRNA medicines, Respiratory syncytial virus, Review [Publication Type], shareholder, Stéphane Bancel, Vaccines

Moderna, shareholder letter, 2024 review, RSV vaccine, COVID-19 vaccine, mRNA medicines, Stéphane Bancel

Merck Acquires WuXi Biologics’ Irish Vaccine Facility in $500M Deal

8 months ago talkbio0Tagged Biological Factors, Facility (object), Ireland, Merck, pharmaceutical manufacturing, Vaccines, WuXi

Merck, WuXi Biologics, vaccine facility, Ireland, $500M deal, pharmaceutical manufacturing

I-Mab Reprioritizes Pipeline, Halts CD73 Antibody Development to Focus on Givastomig

8 months ago talkbio0Tagged 5'-NUCLEOTIDASE, Antibodies, Antibodies, Bispecific, Givastomig, I-Mab, Immunotherapy for cancer, metastatic gastric cancers, pipeline, reshuffle, Uliledlimab

I-Mab, pipeline reshuffle, CD73 antibody, uliledlimab, givastomig, CLDN18.2 x 4-1BB bispecific antibody, cancer immunotherapy, metastatic gastric cancers

I-Mab Shifts Focus Away from CD73 Program to Pursue Strategic Options in CLDN18.2 Space

8 months ago talkbio0Tagged 5'-NUCLEOTIDASE, biotech, development aspects, I-Mab, sanofi, Strategic Options

I-Mab, CD73, CLDN18.2, Sanofi, Strategic Options, Biotech Development

HUTCHMED Divests 45% Stake in Shanghai Hutchison Pharmaceuticals for $608 Million to Focus on Core Oncology Pipeline

8 months ago talkbio0Tagged antibody-targeted therapy, ATTCs, HUTCHMED, Immunostimulating conjugate (antigen), Oncology Pipeline, profitability, Shanghai, Strategic Focus

HUTCHMED, Shanghai Hutchison Pharmaceuticals, divestment, oncology pipeline, antibody-targeted therapy conjugates (ATTCs), strategic focus, profitability.

BioNTech Resolves COVID-19 Vaccine Royalty Disputes with NIH and UPenn

8 months ago talkbio0Tagged Agreement, BioNTech, COVID19 (disease), Disputes, NIH Mouse, Pfizer, Royalty, settlement, UPenn, Vaccines

BioNTech, COVID-19 vaccine, royalty disputes, NIH, UPenn, Pfizer, settlement agreements

FDA Approves Subcutaneous Formulation of Bristol Myers’ Opdivo for Solid Tumor Indications

8 months ago talkbio0Tagged Approved, Cancer Therapeutic Procedure, hyaluronidase, Immunotherapy, Myers, nivolumab, squibb, Subcutaneous Opdivo, United States Food and Drug Administration

FDA approval, subcutaneous Opdivo, Bristol Myers Squibb, cancer treatment, immunotherapy, nivolumab, hyaluronidase

Sanofi and SK Bioscience Enhance Partnership for Next-Generation Pneumococcal Conjugate Vaccines

9 months ago talkbio0Tagged Adult, Bioscience, DKK1 gene, next-generation, PCV21, PCVs, Pediatric brand name, Phase III Testing, pneumococcal conjugate, sanofi, Vaccines

Sanofi, SK Bioscience, Pneumococcal Conjugate Vaccines (PCVs), Next-Generation Vaccines, Pediatric and Adult Populations, Phase III Testing, PCV21

FDA Approves Alhemo: A Breakthrough Once-Daily Treatment for Hemophilia A and B with Inhibitors

9 months ago talkbio0Tagged Alhemo, Approved, concizumab, Hemophilia A, Hemophilia B, inhibitors, once-daily, Prophylactic treatment, subcutaneous, United States Food and Drug Administration

Alhemo, FDA approval, hemophilia A, hemophilia B, inhibitors, concizumab, once-daily treatment, subcutaneous injection, prophylactic treatment

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Advance Development of Atopic Dermatitis Treatment

9 months ago talkbio0Tagged Biological Factors, Clinical stage finding, Dermatitis, Atopic, Ikena Oncology, IMG-007, Implantation procedure, Inmagene Biopharmaceuticals, Merger, Monoclonal Antibodies, Private Room, TNFRSF4 gene

Ikena Oncology, Inmagene Biopharmaceuticals, Merger, Atopic Dermatitis, IMG-007, Monoclonal Antibody, OX40, Biopharmaceuticals, Clinical Stage, Private Placement